Makena Approved to Curb the Risk of Preterm Labor

Makena Approved to Curb the Risk of Preterm Labor

On February 4, 2011, The US Food and Drug Administration approved hydroxyprogesterone caproate injection, Trade name Makena, to reduce the risk for preterm delivery before 37 weeks of pregnancy in women with singleton pregnancy and a history of at least 1 spontaneous preterm birth. This is the first drug approved specifically to reduce this risk.

The drug, a synthetic form of the hormone progesterone, is not intended for use in women with a multiple pregnancy or other risk factors for preterm birth.

To read the full press release issued by the FDA, visit the FDA Website.